Amox%252525252520cv

# Amoxicillin-Clavulanate (Amox-Clav) ## Overview Amoxicillin-clavulanate is a combination beta-lactam antibiotic consisting of an aminopenicillin (amoxicillin) and a beta-lactamase inhibitor (clavulanate potassium). The addition of clavulanate extends the spectrum of activity to include beta-lactamase-producing strains of *S. aureus*, *H. influenzae*, *M. catarrhalis*, and certain anaerobes. ## Primary Indications * Acute bacterial rhinosinusitis * Community-acquired pneumonia * Skin and skin structure infections * Bite wounds (human/animal) * Otitis media (resistant strains) * Urinary tract infections (less common use) ## Adult Dosing Standard dosing is based on the amoxicillin component. * **Mild to moderate infection:** 500 mg every 12 hours or 250 mg every 8 hours. * **Severe infection/Respiratory tract:** 875 mg every 12 hours or 500 mg every 8 hours. * **Extended-release (ER):** 2000 mg every 12 hours (note: ER tablets are not interchangeable with other strengths). * **Maximum:** 2000 mg (amoxicillin component) per 12 hours. ## Pediatric Dosing * **Mild to moderate infection:** 25 mg/kg/day divided every 12 hours (using 200/400 mg strength liquid) or 20 mg/kg/day divided every 8 hours (using 125/250 mg strength liquid). * **Severe infection (e.g., AOM, pneumonia):** 80–90 mg/kg/day divided every 12 hours (using ES-600 formulation). * **Note:** Clavulanate content varies by formulation; always calculate based on the specific concentration available to prevent gastrointestinal toxicity and dosing errors. ## Dose Adjustments * **Renal Impairment (CrCl <30 mL/min):** Avoid the 875 mg tablet. Extend dosing interval or decrease dose based on CrCl. Use 125/250 mg tablets rather than higher-strength formulations to limit clavulanate exposure. * **Hepatic Impairment:** Use with caution; monitor hepatic function periodically. ## Contraindications * Hypersensitivity to amoxicillin, clavulanate, or any penicillin. * History of cholestatic jaundice or hepatic dysfunction associated with amoxicillin-clavulanate therapy. ## Adverse Effects * **Common:** Diarrhea (frequently associated with clavulanate content), nausea, vomiting, skin rash. * **Serious:** *Clostridioides difficile*-associated diarrhea, severe hypersensitivity (anaphylaxis), drug-induced hepatitis/cholestasis, Stevens-Johnson syndrome. ## Key Drug Interactions * **Methotrexate:** Penicillins may decrease renal clearance, increasing risk of methotrexate toxicity. * **Warfarin:** May increase INR and bleeding risk by altering gut flora (vitamin K synthesis); monitor INR closely during therapy. * **Probenecid:** Increases amoxicillin serum concentrations; generally not recommended for co-administration. * **Oral Contraceptives:** Potential for decreased efficacy (minimal evidence base, but commonly cited). ## Monitoring * **Renal/Hepatic:** Periodic baseline and ongoing assessment in long-term therapy. * **Allergic reaction:** Immediate assessment for rash, dyspnea, or anaphylaxis. * **Efficacy:** Monitor for resolution of clinical symptoms within 48–72 hours. ## Clinical Pearls * **Formulation Warning:** 250 mg tablets and 250 mg chewable tablets are **not** interchangeable because they contain different amounts of clavulanate. * **Diarrhea Management:** Administering with food may reduce the frequency of gastrointestinal side effects. * **Clavulanate Ceiling:** Excessive clavulanate can cause diarrhea; use the High-Dose (90 mg/kg) formulation designed specifically for resistant infections to maintain appropriate amoxicillin-to-clavulanate ratios. * **Not for MRSA:** Amox-Clav provides no coverage against Methicillin-Resistant *Staphylococcus aureus* (MRSA). *** **Educational Disclaimer:** This information is for educational purposes only. Clinical guidelines and local antimicrobial susceptibility patterns vary by region. Always verify specific dosing, safety, and drug compatibility through current institutional protocols, electronic medical record resources, or primary FDA-approved prescribing information before administration.